Pharmacology of myocardial calcium-handling

Julia Vogler1, Lars Eckardt

  • 1Division of Rhythmology, Department of Cardiology and Angiology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149 Muenster, Germany. julia.vogler@ukmuenster.de

Insights

Impaired myocardial calcium handling is key in heart diseases. Treatments aim to restore calcium homeostasis using current and novel pharmacologic agents targeting calcium-dependent pathways.

Area of Science:

  • Cardiovascular Pharmacology
  • Molecular Cardiology
  • Biomedical Science

Background:

  • Disturbed myocardial calcium (Ca2+) handling is a hallmark of cardiovascular diseases like heart failure and hypertrophy.
  • Abnormal Ca2+ handling also contributes to tachyarrhythmias.
  • Restoring myocardial Ca2+ homeostasis is a primary therapeutic goal.

Purpose of the Study:

  • To review current pharmacologic agents for restoring myocardial Ca2+ homeostasis.
  • To discuss the mechanisms of action of these agents.
  • To highlight emerging substances for cardiovascular disease treatment.

Main Methods:

  • Literature review of pharmacologic agents.
  • Analysis of mechanisms targeting Ca2+-dependent signaling pathways.
  • Synthesis of information on established and novel treatments.

Main Results:

  • Identified key pharmacologic strategies targeting myocardial Ca2+ homeostasis.
  • Detailed mechanisms of action for existing drugs.
  • Summarized potential of new therapeutic substances.

Conclusions:

  • Pharmacologic interventions targeting myocardial Ca2+ homeostasis are crucial for cardiovascular diseases.
  • Understanding Ca2+ handling mechanisms informs drug development.
  • Novel agents show promise for improved treatment of heart conditions.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...